Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.56M Buy
+150,000
New +$6.36M ﹤0.01% 3821
2021
Q4
– Sell
-47,153
Closed -$2.58M – 10607
2021
Q3
$2.58M Buy
+47,153
New +$2.63M ﹤0.01% 3352
2020
Q2
– Sell
-47,153
Closed -$2.08M – 8273
2020
Q1
$2.08M Buy
+47,153
New +$1.84M ﹤0.01% 2723
2019
Q1
– Sell
-37,722
Closed -$1.38M – 8069
2018
Q4
$1.38M Sell
37,722
-56,584
-60% -$2.1M ﹤0.01% 3395
2018
Q3
$3.79M Hold
94,306
– – ﹤0.01% 2610
2018
Q2
$3.62M Hold
94,306
– – ﹤0.01% 2626
2018
Q1
$3.23M Buy
+94,306
New +$3.31M ﹤0.01% 2712
2017
Q2
– Sell
-42,437
Closed -$1.3M – 7917
2017
Q1
$1.3M Buy
+42,437
New +$1.31M ﹤0.01% 3321

Other funds holding QGEN

UBS Group's QGEN Position: Q3 2026 in Review

UBS Group reduced its Qiagen (QGEN) stake by 34% in Q3 2026, selling an estimated $49.3M and leaving 2,257,245 shares worth $98.8M. The position accounts for 0.01% of the portfolio, ranked #1103.

UBS Group first reported a position in QGEN in Q1 2017 and has held it in 39 quarters since. The position peaked at $215M in Q1 2020. 366 funds tracked by Wall St. Rank hold QGEN as of Q3 2026.

  • UBS Group held 2,257,245 shares of Qiagen worth $98.8M as of Q3 2026.
  • UBS Group sold 1,161,950 Qiagen shares in Q3 2026, an estimated $49.3M.
  • Qiagen made up 0.01% of UBS Group's portfolio in Q3 2026, its #1103 holding.
  • UBS Group first reported a position in Qiagen in Q1 2017 and has held it in 39 quarters since.
  • UBS Group's Qiagen position peaked at $215M in Q1 2020.
  • 366 funds tracked by Wall St. Rank held Qiagen as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.